Chronic Respiratory Disease Drug Development Market 2019 By Top Companies AstraZeneca, GlaxoSmithKline and Galapagos

Albany, NY, 18th January : Recent research and the current scenario as well as future market potential of "Chronic Respiratory Disease Drug Development Pipeline Review, 2018" globally.

This report provides an overview of the pipeline landscape for chronic respiratory diseases. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF).

Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=1957070

Asthma is a chronic disease involving the airways in the lungs. Symptoms include shortness of breath, chest tightness or pain, chronic coughing and trouble sleeping due to coughing or wheezing. The predisposing factors include family history, being overweight, smoking, exposure to exhaust fumes or other types of pollution and exposure to occupational triggers, such as chemicals used in farming, hairdressing and manufacturing. There are 275 products in development for this indication.

COPD is a group of lung diseases. It is characterized by inability to completely breathe out air from the lungs, leading to shortness of breath and blocked airflow to the lungs. Other symptoms include cough, fatigue and chest pain. The disease tends to worsen over time, increasing complications. The main risk factor is smoking. Exposure to chemicals and air pollution also contribute in the development of COPD. There are 187 products in development for this indication.

IPF is a progressive and fatal disease characterized by inflammation and scarring of lung tissue and loss of lung function. Symptoms of IPF include dry cough, shortness of breath, especially during or after physical activity, lasting tiredness and weight loss. Risk factors include smoking, environmental exposure, viral infections, family history and abnormal acid reflux. There are 136 products in development for this indication.

Molecular targets in development for chronic respiratory diseases include phosphodiesterases, adrenergic receptors, interleukins and chemokine receptors. Companies operating in this pipeline space include AstraZeneca, GlaxoSmithKline and Galapagos.

View Complete TOC with tables & Figures @ https://www.researchmoz.us/chronic-respiratory-disease-drug-development-pipeline-review-2018-report.html/toc

Scope

Which companies are the most active within each pipeline?
Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy

Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Table of Contents

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 11

2 Introduction 12
2.1 Chronic Respiratory Disease Report Coverage 12
2.2 Asthma - Overview 12
2.3 Chronic Obstructive Pulmonary Disease (COPD) - Overview 12
2.4 Idiopathic Pulmonary Fibrosis - Overview 12

3 Therapeutics Development 13
3.1 Asthma 13
3.2 Chronic Obstructive Pulmonary Disease (COPD) 33
3.3 Idiopathic Pulmonary Fibrosis 51

4 Therapeutics Assessment 65
4.1 Asthma 65
4.2 Chronic Obstructive Pulmonary Disease (COPD) 81
4.3 Idiopathic Pulmonary Fibrosis 94

5 Companies Involved in Therapeutics Development 106
5.1 Asthma 106
5.2 Chronic Obstructive Pulmonary Disease (COPD) 172
5.3 Idiopathic Pulmonary Fibrosis 223

Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=1957070

6 Dormant Projects 259
6.1 Asthma 259
6.2 Chronic Obstructive Pulmonary Disease (COPD) 279
6.3 Idiopathic Pulmonary Fibrosis 302

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

Mr. Nachiket Ghumare,
ResearchMoz,
90 State Street, Albany NY, United States,
Tel: +1-518-621-2074,
USA-Canada Toll Free: 866-997-4948,
Email: sales@researchmoz.us,
Follow me on : https://marketinfo247.wordpress.com/

This release was published on openPR.